Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

A Randomized Crossover Trial of Bright Light Therapy in Irritable Bowel Syndrome

A legfontosabb adatok

Ki végzi
Medical University of South Carolina
Hol
Charleston (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Befejeződött
Résztvevők
5 fő vett részt
Kezdés
2025. jún. 11.
Befejezés
2026. márc. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Re-Timer glasses
  • Placebo Device
A regiszteradat frissítve
2026. április 7.

Ki vehet részt

Életkor
18 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • 18-65 years old
  • Irritable Bowel Syndrome based on Rome IV diagnostic criteria
  • Mild to severe IBS symptom severity based on IBS-SSS greater than or equal to 75 17
  • Late chronotype based on the Munich Chronotype Questionnaire (Corrected Midpoint of Sleep > 4:00h) 18 Exclusion Criteria
  • Subject that are pregnant or plan to become pregnant
  • Night shift workers or people who have crossed more than 2 time zones in the previous 4 weeks
  • Regular use of medications that affect intestinal permeability, and/or endogenous melatonin including metoclopramide, NSAIDs, beta blockers, antibiotics, psychotropic medications, hypnotics and exogenous melatonin products during 4 weeks prior to the study
  • Any major organ disease - known renal impairment, diabetes, liver disease, or significant cardiac failure (NY classification stage III/IV), inflammatory bowel disease or celiac disease per chart review and/or medical history
  • Diagnosis of narrow angle glaucoma or retinal disorders or demonstrated symptoms indicative of these diagnosis during the eligibility screening
  • Moderate to severe depression (score ≥ 21 or any endorsement of suicidal intent on the Beck Depression Inventory) 19
  • Sleep apnea (score high risk in 2 or more categories of the Berlin Questionnaire) 20
  • Restless leg syndrome (score ≥ 15 on the IRLS Study Group Rating Scale) 21
  • Inability or unwillingness of subject to sign an informed consent

Helyszínek itt: Egyesült Államok

  • Medical University of South CarolinaCharleston, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this research study is to assess whether morning bright light therapy (BLT) using a wearable device called a Re-Timer could potentially improve Irritable Bowel Syndrome (IBS) symptoms and decrease intestinal permeability (leaky gut). Morning bright light therapy will be administrated through a safe-wearable glasses device called a Re-Timer. The Re-Timer glasses are lightweight and deliver blue-green light at 500nm, mimicking exposure to natural light.

A vizsgálat 2 csoportja

  • Re-Timer Device (Bright Light Therapy)A vizsgált kezelés

    Morning bright light therapy will be administrated through a safe wearable device called a Re-timer. The Re-Timer glasses are lightweight and deliver blue-green light at 500nm, mimicking exposure to natural light. The device emits light at a higher wavelength than the UV range and has a UV filter for added safety. Subjects will be asked to wear the glasses for one hour each morning per day for 7 days a week. They will wear the device for a total of 14 days to receive the full therapeutic effect. Additionally, subjects will be asked to complete the light therapy the first hour of being awake and remain indoors while using the device. Participants will be informed that they can wear the device freely throughout their home or work environment but should avoid activities that could potentially be harmful (i.e., driving, contact sports, operating heavy machinery).

    Kezelés: Re-Timer glasses

  • Placebo device (non Bright Light Therapy)Placebo, összehasonlításként

    Subjects will be asked to wear glasses that do not provide Bright Light Therapy for one hour each morning per day for 7 days a week as recommended by the manufacturer. They will wear the device for a total of 14 days to receive the full therapeutic effect. Additionally, subjects will be asked to complete the light therapy the first hour of being awake and remain indoors while using the device. Participants will be informed that they can wear the device freely throughout their home or work environment but should avoid activities that could potentially be harmful (i.e., driving, contact sports, operating heavy machinery).

    Kezelés: Placebo Device

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. április 7.